March 2022
- Exclusive
- Sharemarket
Anagenics boss defends Lyramid sale to Panamanian holding company
After Monday’s resignation, Maria Halasz said via a lawyer that a deal to sell a subsidiary to a Panamanian holding company was in shareholders’ interests.
- Tom Richardson
September 2020
Cellmid's COVID-19 highs ebb away
The contender for the worst capital raising of recent years is looking to restructure its business as shares head lower.
- Tom Richardson
June 2020
Cellmid's Chinese takeaway still under review
Shares in the reseller of COVID-19 antibody tests have halved since an April capital raising at 22 cents.
- Tom Richardson
May 2020
Cellmid hanging on TGA approval, like we said
Cellmid took great exception to Rear Window's column of May 7.
- Joe Aston
Cellmid's Chinese takeaway under review
Cellmid raised $6.3 million in capital to purchase COVID-19 antibody tests from a Chinese manufacturer with a mixed track record.
- Tom Richardson
April 2020
Silly season for ASX biotechs
There's nothing like a pandemic to bring every biotech hopeful out of the shadows.
- Myriam Robin
August 2018
Former Coles CEO Dennis Eck backs Cellmid's Chinese pharma push
A former CEO of the Coles retail brands has more skin in the game as ASX group Cellmid eyes China and the US for anti hair-loss products and steps up a push into anti-wrinkle treatements.
- Updated
- Simon Evans
July 2018
Blue Ocean raising for anti-aging products company
Consumer health business Cellmid is in front of fund managers seeking an equity injection on Monday.
- Updated
- Sarah Thompson and Anthony Macdonald
March 2014
How US biotechnology bull run will affect Australia
The lower Aussie dollar, a well regarded local clinical trials industry, and a frothy US biotechnology industry, are combining to make early stage Australian life science companies attractive.
- Updated
- Jessica Gardner
May 2013
New hero for naked noggins
Good news for the follicularly challenged: soon Shane Warne can part ways with Advanced Hair Studios and the Channel 9 make-up department won’t be applying Kiwi shoe polish to the noggins of Karl Stefanovic and yours truly.
March 2013
Noble Oak readied for IPO
The 135-year old Noble Oak was demutualised in 2011 before attracting Intrasia Capital as an investor. Intrasia is chaired by Graeme Robertson, who partnered the Millner family in New Hope Corporation more than 30 years ago. New Hope is now a $3.5 billion coal play and Robertson has cashed out to pursue the likes of Noble Oak.
- Sarah Thompson and Anthony Macdonald
February 2012
Biotechs making a steady recovery
There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.
- Updated
- Brendon Lau